Page last updated: 2024-11-07

camphora

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

camphora: a component of Guanxingao, a kind of traditional Chinese rubber electuary medicine which is able to either cure or guard against coronary heart disease and angina pectoris [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(R)-camphor : The (R)- enantiomer of camphor. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
Laurus camphoraspecies[no description available]LauraceaeA family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH]
Camphora camphoraspecies[no description available]LauraceaeA family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH]
Camphoragenusa component of Guanxingao, a kind of traditional Chinese rubber electuary medicine which is able to either cure or guard against coronary heart disease and angina pectoris[MeSH]LauraceaeA family of mainly aromatic evergreen plants in the order Laurales. The laurel family includes 2,200 species in 45 genera and from these are derived medicinal extracts, essential oils, camphor and other products.[MeSH]

Cross-References

ID SourceID
PubMed CID159055
CHEMBL ID504760
CHEBI ID15396
SCHEMBL ID16069
MeSH IDM0400824

Synonyms (151)

Synonym
CHEBI:15396 ,
(r)-(+)-camphor
camphor(d)
(1r,4r)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
(1r)-(+)-camphor
(+)-bornan-2-one
(r)-camphor
(1r,4r)-camphor
camphor, (1r,4r)-(+)-
d-(+)-camphor
bicyclo(2.2.1)heptan-2-one, 1,7,7-trimethyl-, (1r,4r)-
japanese camphor
fema no. 2230
(+)-2-bornanone
bicyclo(2.2.1)heptan-2-one, 1,7,7-trimethyl-, (1theta)-
d-2-camphanone
alcanfor
bicyclo(2.2.1)heptan-2-one, 1,7,7-trimethyl-, (1r)-
camphor, (+)-
camphor, d-
ai3-01698
einecs 207-355-2
d-2-bornanone
(1r,4r)-1,7,7-trimethylbicyclo(2.2.1)heptan-2-one
(1r)-camphor
camphor usp
BSPBIO_001923
NCGC00090681-01
un2717
einecs 244-350-4
ai3-18783
epa pesticide chemical code 015602
bicyclo(2.2.1)heptane-2-one, 1,7,7-trimethyl-
hsdb 37
(+-)-camphor
caswell no. 155
kampfer [german]
huile de camphre [french]
brn 1907611
einecs 200-945-0
brn 3196099
2-kamfanon [czech]
d-camphor
464-49-3
(+)-camphor ,
(+/-)-camphor, >=95.5%
d-camphor, >=97%, fg
(1r)-(+)-camphor, 98%
NCGC00090681-04
camphora
DB01744
camphor (natural)
natural camphor
dextrocamphor
camphor d-form
camphor, 96%
KBIO3_001143
SPECTRUM3_000322
SPECTRUM2_000383
SPBIO_000565
dl-camphor
NCGC00090681-02
NCGC00090681-06
(+/-)-camphor, meets analytical specification of ph.??eur., bp, racemic, >=95% (gc)
(1r,4r)-4,7,7-trimethylbicyclo[2.2.1]heptan-3-one
NCGC00090681-07
d(+)-camphor
d-camphor [jan]
nsc 755918
unii-n20hl7q941
n20hl7q941 ,
NCGC00257061-01
dtxsid4024721 ,
tox21_303052
cas-464-49-3
dtxcid804721
synthetic camphor
camphor laurel
laurus camphora
nsc-755918
camphor, dl-
camphor, racemic
fema no. 4513
camphor (synthetic)
camphorwood
cinnamonum camphora
camphora camphora
CHEMBL504760
NCGC00259736-01
tox21_202187
pharmakon1600-01500156
camphor (1r)
nsc755918
tox21_110995
AKOS016001972
ec 200-945-0
4-07-00-00213 (beilstein handbook reference)
camphor [usp]
camphor, synthetic [un2717] [flammable solid]
zang qi
5tjd82a1et ,
0-07-00-00135 (beilstein handbook reference)
unii-5tjd82a1et
8008-51-3
(+)-camphor [fcc]
d-camphor [ep monograph]
camphor [usp-rs]
d-camphor [who-dd]
camphora [hpus]
(1r,4r)-(+)-camphor
camphor d-form [mi]
d-camphor [fhfi]
(1r)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
camphor, (+/-)-
camphor [who-dd]
camphor, racemic [ep monograph]
camphor [mi]
camphor [hsdb]
camphor [inci]
dl-camphor [jan]
bdbm36263
SCHEMBL16069
tox21_110995_1
NCGC00090730-03
CS-4779
( s)-camphor
HY-B1173
AB00443849_03
bicyclo[2.2.1]heptan-2-one, 1,7,7-trimethyl-, (1r,4r)-
camphor (racemic), european pharmacopoeia (ep) reference standard
d-camphor, analytical reference material
camphor (dl), primary pharmaceutical reference standard
camphor, united states pharmacopeia (usp) reference standard
(+/-)-camphor, purum, synthetic, >=95.0% (gc)
(+/-)-camphor, saj first grade, >=96.0%
(+)-camphor, purum, natural, >=97.0% (sum of enantiomers, gc)
d-camphor, pharmaceutical secondary standard; certified reference material
(+/-)-camphor, puriss., 96-101%
d-camphor, natural, 96%, fg
d-camphor; (1r,4r)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-one
SBI-0206668.P002
E75796
Q27089415
camphor-(+)
d-(+)-camphor;(1r)-(+)-camphor
BS-42283
d-camphor 1000 microg/ml in methanol
EN300-84949
?dl-camphor
camphor, racemic (ep monograph)
Z1255434759

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
camphorA cyclic monoterpene ketone that is bornane bearing an oxo substituent at position 2. A naturally occurring monoterpenoid.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
(+)-camphor biosynthesis111
(+)-camphor biosynthesis112

Protein Targets (10)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency43.53560.006038.004119,952.5996AID1159521
TDP1 proteinHomo sapiens (human)Potency5.88210.000811.382244.6684AID686978; AID686979
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency25.11890.011212.4002100.0000AID1030
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency61.13060.003041.611522,387.1992AID1159552
estrogen nuclear receptor alphaHomo sapiens (human)Potency28.22630.000229.305416,493.5996AID743080; AID743091
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency6.27500.005612.367736.1254AID624032; AID624044
lamin isoform A-delta10Homo sapiens (human)Potency10.00000.891312.067628.1838AID1487
Cellular tumor antigen p53Homo sapiens (human)Potency1.18830.002319.595674.0614AID651631
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily A member 1Homo sapiens (human)IC50 (µMol)530.00000.05102.47257.5000AID482153; AID482155
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Transient receptor potential cation channel subfamily V member 3Homo sapiens (human)Activity100.000010.000010.000010.0000AID500216
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (145)

Processvia Protein(s)Taxonomy
monoatomic ion transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellular calcium ion homeostasisTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cell surface receptor signaling pathwayTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to coldTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to xenobiotic stimulusTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to organic cyclic compoundTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium-mediated signalingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
response to painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
thermoceptionTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
detection of chemical stimulus involved in sensory perception of painTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
protein homotetramerizationTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to hydrogen peroxideTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
cellular response to organic substanceTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
response to temperature stimulusTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
negative regulation of hair cycleTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
calcium ion transmembrane transportTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
positive regulation of calcium ion importTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
calcium ion import across plasma membraneTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (38)

Processvia Protein(s)Taxonomy
calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
intracellularly gated calcium channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
identical protein bindingTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
temperature-gated cation channel activityTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
calcium channel activityTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
protein bindingTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (23)

Processvia Protein(s)Taxonomy
plasma membraneTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
stereocilium bundleTransient receptor potential cation channel subfamily A member 1Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
cytoplasmTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
lysosomeTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
receptor complexTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
plasma membraneTransient receptor potential cation channel subfamily V member 3Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (96)

Assay IDTitleYearJournalArticle
AID1124987Antiviral activity against rimantidine, amantadine-resistant Influenza A virus (A/California/07/09(H1N1)) pdm09 infected in MDCK cells assessed as inhibition of viral replication by hemagglutinin titer assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1112518Displacement of [3H]TBOB binding to GABA receptor in Musca domestica (house fly) heads homogenates assessed as [3H]TBOB binding at 500 uM incubated for 90 min by scintillation counting method2012Pest management science, Aug, Volume: 68, Issue:8
Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.
AID1090509Antifungal activity against Colletotrichum acutatum assessed as growth inhibition at 4 uL in 2 mM acetone by direct bioautography2006Journal of agricultural and food chemistry, Sep-06, Volume: 54, Issue:18
Chemical composition and antifungal activity of Salvia macrochlamys and Salvia recognita essential oils.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1103236Antifungal activity against Botryotinia fuckeliana assessed as mycelial growth inhibition after 4 to 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID360503Antioxidant activity assessed as DPPH radical scavenging activity1995Journal of natural products, Nov, Volume: 58, Issue:11
Santolindiacetylene, a polyacetylene derivative isolated from the essential oil of Santolina canescens.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID227701Anticonvulsant activity; NC denotes that compound is not classified2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Topological virtual screening: a way to find new anticonvulsant drugs from chemical diversity.
AID482153Antagonist activity at TRPA1 channel assessed as inhibition of mustard oil-induced currents2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID386036Inhibition of capsaicin-induction of paw lifting in Swiss mouse2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1090508Antifungal activity against Colletotrichum fragariae assessed as growth inhibition at 4 uL in 2 mM acetone by direct bioautography2006Journal of agricultural and food chemistry, Sep-06, Volume: 54, Issue:18
Chemical composition and antifungal activity of Salvia macrochlamys and Salvia recognita essential oils.
AID1124988Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/California/07/09(H1N1)) pdm092014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1151042Antinociceptive activity in male white mouse at 100 mg/kg, sc by hot plate test1976Journal of medicinal chemistry, Aug, Volume: 19, Issue:8
(-)-3-Isothujone, a small nonnitrogenous molecule with antinociceptive activity in mice.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1124986Cytotoxicity against MDCK cells assessed as cell viability after 48 hrs by MTT assay2014Bioorganic & medicinal chemistry, Apr-01, Volume: 22, Issue:7
Camphor-based symmetric diimines as inhibitors of influenza virus reproduction.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID332912Antimicrobial activity Propionibacterium acnes ATCC 11827 after 2 days by broth dilution method1994Journal of natural products, Jan, Volume: 57, Issue:1
Naturally occurring antiacne agents.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID778917Antiviral activity against Influenza virus A/California/07/09 (H1N1)pdm09 infected in MDCK cells assessed as inhibition of viral replication incubated for 1 hr prior to viral infection measured after 48 hrs by hemagglutination reaction2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1103232Antifungal activity against Rhizoctonia solani assessed as mycelial growth inhibition after 4 to 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID336478Inhibition of COX2 at 100 uM by scintillation proximity assay2002Journal of natural products, Nov, Volume: 65, Issue:11
Screening of ubiquitous plant constituents for COX-2 inhibition with a scintillation proximity based assay.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1426031Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/California/07/09(H1N1))2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID386034Effect on capsaocin-induction of allodynia in Swiss mouse2007Proceedings of the National Academy of Sciences of the United States of America, Aug-14, Volume: 104, Issue:33
4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1581191Agonist activity at mouse TRPV3 expressed in HEK293 cells assessed as increase in calcium influx at 10 uM incubated for 1 min by Fluo-4-AM dye based FLIPR assay2020Journal of medicinal chemistry, 01-09, Volume: 63, Issue:1
Discovery of Nonpungent Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist as Strong Topical Analgesic.
AID1426029Cytotoxicity against MDCK cells after 48 hrs by MTT assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1112517Toxicity to Musca domestica (house fly) applied to pronotum assessed as compound level per fly causing insect mortality measured after 24 hr2012Pest management science, Aug, Volume: 68, Issue:8
Quantitative structure-activity relationships of monoterpenoid binding activities to the housefly GABA receptor.
AID500216Agonist activity at TRPV32005Nature chemical biology, Jul, Volume: 1, Issue:2
Sensing with TRP channels.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID778912Toxicity in Escherichia coli BL21(DE3) expressing pET36b-gfp assessed as inhibition of IPTG-induced reporter protein GFP synthesis at 2 uM after 1.5 hrs by fluorophotometry relative to control2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1103229Antimicrobial activity against Escherichia coli ATCC 8739 assessed as growth inhibition after 24 hr by broth microdilution method2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID1090507Antifungal activity against Colletotrichum gloeosporioides assessed as growth inhibition at 4 uL in 2 mM acetone by direct bioautography2006Journal of agricultural and food chemistry, Sep-06, Volume: 54, Issue:18
Chemical composition and antifungal activity of Salvia macrochlamys and Salvia recognita essential oils.
AID1103228Antimicrobial activity against Pseudomonas aeruginosa ATCC 9027 assessed as growth inhibition after 24 hr by broth microdilution method2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID1103227Antimicrobial activity against Candida albicans ATCC 14053 assessed as growth inhibition after 24 hr by broth microdilution method2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID492140Antioxidant activity assessed as formazan formation induced absorbance changes at 25 ppm at 570 nm at 37 degC for 6 hrs by MTT assay2010Journal of natural products, Jul-23, Volume: 73, Issue:7
An efficient and economical MTT assay for determining the antioxidant activity of plant natural product extracts and pure compounds.
AID1426030Antiviral activity against Influenza A virus (A/California/07/09(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1103231Antimicrobial activity against Staphylococcus aureus ATCC 6538 assessed as growth inhibition after 24 hr by broth microdilution method2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID482155Antagonist activity at human TRPA1 channel assessed as inhibition of thymol-induced response2010Journal of medicinal chemistry, Jul-22, Volume: 53, Issue:14
Transient receptor potential ankyrin 1 (TRPA1) channel as emerging target for novel analgesics and anti-inflammatory agents.
AID1426033Selectivity index, ratio of CTD50 for MDCK cells to ED50 for Influenza A virus (A/Puerto Rico/8/34(H1N1))2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID778915Induction of mutagenicity in Escherichia coli BL21(DE3) expressing pRAC-gfp assessed as modulation of reporter protein GFP synthesis at 2 uM incubated for 1.5 hrs followed by plasmid maturation measured after 1.5 hrs by fluorophotometry2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1426032Antiviral activity against Influenza A virus (A/Puerto Rico/8/34(H1N1)) infected in MDCK cells assessed as inhibition of viral replication after 48 hrs by hemagglutination test2017European journal of medicinal chemistry, Feb-15, Volume: 127Aliphatic and alicyclic camphor imines as effective inhibitors of influenza virus H1N1.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1103234Antifungal activity against Fusarium graminearum assessed as mycelial growth inhibition after 4 to 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID1103226Induction of growth of Fusarium graminearum after 4 to 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID1103235Antifungal activity against Fusarium oxysporum f. sp. lycopersici assessed as mycelial growth inhibition after 4 to 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID778916Selectivity index, ratio of CTD50 for MDCK cells to EC50 for Influenza A virus California/07/09(H1N1) pdm09 infected in MDCK cells2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1103230Antimicrobial activity against Staphylococcus epidermidis ATCC 12228 assessed as growth inhibition after 24 hr by broth microdilution method2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID1103233Antifungal activity against Fusarium culmorum assessed as mycelial growth inhibition after 4 to 12 days2004Journal of agricultural and food chemistry, Jun-02, Volume: 52, Issue:11
chemical composition, plant genetic differences, antimicrobial and antifungal activity investigation of the essential oil of Rosmarinus officinalis L.
AID778918Cytotoxicity against MDCK cells after 48 hrs by MTT assay2013Bioorganic & medicinal chemistry, Nov-01, Volume: 21, Issue:21
New quaternary ammonium camphor derivatives and their antiviral activity, genotoxic effects and cytotoxicity.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (31)

TimeframeStudies, This Drug (%)All Drugs %
pre-19902 (6.45)18.7374
1990's3 (9.68)18.2507
2000's7 (22.58)29.6817
2010's10 (32.26)24.3611
2020's9 (29.03)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 101.29

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index101.29 (24.57)
Research Supply Index3.50 (2.92)
Research Growth Index4.96 (4.65)
Search Engine Demand Index178.79 (26.88)
Search Engine Supply Index2.01 (0.95)

This Compound (101.29)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews2 (6.25%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (93.75%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]